Journal of thrombosis and haemostasis : JTH
-
J. Thromb. Haemost. · Dec 2015
Randomized Controlled Trial Comparative StudyOral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial.
The AMPLIFY trial compared apixaban with enoxaparin followed by warfarin for the treatment of acute venous thromboembolism (VTE). ⋯ The results of this subgroup analysis suggest that apixaban is a convenient option for cancer patients with VTE. However, additional studies are needed to confirm this concept and to compare apixaban with low molecular weight heparin in these patients.
-
J. Thromb. Haemost. · Dec 2015
Randomized Controlled TrialBemiparin for thromboprophylaxis after benign gynecologic surgery: a randomized clinical trial.
Venous thromboembolism (VTE) is the leading cause of mortality and morbidity in women following gynecologic surgery. ⋯ Bemiparin was an effective thromboprophylactic agent for preventing venous thrombosis after benign gynecologic surgery.
-
J. Thromb. Haemost. · Dec 2015
Ex vivo addition of fibrinogen concentrate improves the fibrin network structure in plasma samples taken during liver transplantation.
Optimal hemostatic management during orthotopic liver transplantation (OLT) remains a challenge. The cause of bleeding during OLT is multifactorial, and may include hemostatic imbalance. Fibrinogen concentrates are increasingly being used to control perioperative bleeding during OLT. However, administration is based on arbitrary thresholds of fibrinogen levels. Importantly, studies on fibrin clot structure during OLT are lacking. ⋯ Ex vivo addition of fibrinogen concentrate during OLT substantially improves the structural properties of the fibrin clot, which, particularly after reperfusion, shows hypocoagulable features. These data support the use of fibrinogen concentrate to control bleeding complications during OLT.
-
J. Thromb. Haemost. · Dec 2015
Four-factor prothrombin complex concentrate reverses apixaban-associated bleeding in a rabbit model of acute hemorrhage.
Apixaban is a direct factor Xa inhibitor approved for the treatment and prevention of thromboembolic disease. There is a lack of data regarding its reversal in cases of acute bleeding or prior to emergency surgery that needs addressing. ⋯ In this rabbit model of acute hemorrhage, 4F-PCC showed potential for reversing the bleeding effects of apixaban. Clinical data in apixaban-treated patients are needed to confirm these results.